BrainsWay (BWAY) announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company’s Deep Transcranial Magnetic Stimulation, TMS, technology to treat alcohol use disorder, AUD, patients. The outcomes were reported in a publication in the Brain Stimulation journal entitled, “Accelerated deep TMS in alcohol use disorder: A preliminary pilot trial targeting the dorsal anterior cingulate cortex increases neural target engagement and abstinence.” In the follow-up period after treatment, subjects receiving accelerated Deep TMS showed notably better improvements when compared to those treated by other means. The better outcomes were seen in several important areas, including lower percentages of heavy drinking days and regular drinking days, as well as lower relapse rates
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BWAY:
- BrainsWay’s Deep TMS Shows Promise in Pain Reduction
- Brainsway announces publication on pain reduction with Deep TMS therapy
- Brainsway price target raised to $13.40 from $12.60 at Ladenburg
- BrainsWay Reports Strong Q3 2024 Revenue Growth
- BrainsWay’s Strong Q3 Growth and Strategic Expansion
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
